Business
Graphite Bio Reports Recent Business Progress and Fourth Quarter and Fiscal Year 2021 Financial Results
Patient enrollment in Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease ongoing at multiple sites; dosing of first patient now planned for
About this update from Lenz Therapeutics, Inc.
[{"type":"text","content":"\nPatient enrollment in Phase 1/2 CEDAR clinical trial of GPH101 for sickle cell disease ongoing at multiple sites; dosing of first patient now planned for second half of 2022, with initial proof-of-concept data anticipated in 2023\n\nPrioritized R&D to maximize capabilities of company’s next-generation gene editing platform and significantly impact patient outcomes\n\nBolstered company leadership with hiring of chief financial officer and chief of staff, and promotion of chief people officer\n\n$378.7 million in cash, cash equivalents and restricted cash as of December 31, 2021; cash runway extended into the fourth quarter of 2024\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nGraphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on developing therapies that harness targeted gene integration to treat or cure serious diseases, today reported recent business progress and fourth quarter and fiscal year 2021 financial results.\n\n“2021 was a pivotal year in our company’s history as we established ourselves as a public company and initiated the clinical trial for our lead candidate, GPH101 for sickle cell disease. In 2022, we remain focused on advancing our research and development priorities, in particular the execution of our Phase 1/2 CEDAR clinical trial of GPH101. We continue to work toward demonstrating that our unique gene correction approach to reduce sickle hemoglobin production and restore adult hemoglobin expression has the potential to achieve the ideal genetic outcome and provide a definitive cure for patients with sickle cell disease,” said Josh Lehrer, M.D., M.Phil., chief executive officer of Graphite Bio.\n\n“Over the course of this year, we look forward to sharing more information about our research programs, including GPH102, our differentiated gene replacement program for beta-thalassemia,” Lehrer continued. “With our updated pipeline priorities, our programs now even more closely align with our goal of transforming the gene therapy treatment paradigm – from how we develop and manufacture these individualized therapies to how we deliver them to patients. Our mission is to make ‘one dose, one cure’ a reality for as many patients as possible with serious diseases and inadequate treatments.”\n\nProgram Updates\n\nGPH101 for Sickle Cell Disease\n\n\nContinued patient e...